UPDATE: Lilly to appeal British rejection of Alimta
Eli Lilly and Co. said today it will appeal a decision by Great Britain’s National Institute for Health and Clinical Excellence to not recommend its Alimta lung cancer drug. The Indianapolis drugmaker said it was disappointed with the decision, and that the decision would limit patient treatment. The agency, which is influential with doctors, said […]